Cryolife On-X
In late February, CryoLife Inc. (NYSE:CRY) landed CE Mark approval allowing its On-X ascending aortic prosthesis (AAP) to return to the market in Europe.
The On-X AAP is indicated for treating diseased, damaged or malfunctioning native or prosthetic heart valves in the aortic position involving an ascending aortic aneurysm. The associated aortic diseases it’s designed to treat coexist in as many as 10% of all aortic valve replacements, according to the company.
The device had been off the market there since late 2016. CryoLife entered the valve market with the purchase of On-X Life Technologies in January 2016, but dealt with legal battles over a $10 million escrow account connected with the merger in 2017.